In particular, anti-CD44v6 CAR T-cell immunotherapy trials for multiple cancers (NCT04427449), r/r AML, MM (NCT04097301) and breast cancer (NCT02046928) are ongoing, representing promising strategies worth to be extended to T-ALL and other CD44+ T-cell malignancies, once safety concerns are solved and efficacy proved. The gene discussed is CD44; the disease is acute myeloid leukemia.